2411. Expanded Susceptibility and Resistance Mechanism Testing Among Carbapenem-Resistant Enterobacteriaceae in Connecticut, 2017
Durante A, Maloney M, Leung V, Macierowski B, Noel D, Razeq J, Banach D. 2411. Expanded Susceptibility and Resistance Mechanism Testing Among Carbapenem-Resistant Enterobacteriaceae in Connecticut, 2017. Open Forum Infectious Diseases 2018, 5: s721-s721. PMCID: PMC6253689, DOI: 10.1093/ofid/ofy210.2064.Peer-Reviewed Original ResearchState public health laboratoriesLaboratory Standards Institute breakpointsPolymerase chain reaction testingReal-time polymerase chain reaction testingCeftazidime/avibactamCarbapenem-resistant EnterobacteriaceaePublic health laboratoriesCRE isolatesEmpiric treatmentCP-CRECarbapenemase testingReaction testingHealth laboratoriesCarbapenemase productionCarbapenem inactivation methodSusceptibility testingCommon carbapenemasesBroth microdilutionNon-CPDisk diffusionInactivation methodCreAntibiogramClinicalAvibactam2396. Fosfomycin Resistance Among Carbapenem-Resistant Enterobacteriaceae Clinical Isolates in Connecticut, 2017
Snayd M, Leung V, Maloney M, Durante A, Macierowski B, Noel D, Muyombwe A, Razeq J, Banach D. 2396. Fosfomycin Resistance Among Carbapenem-Resistant Enterobacteriaceae Clinical Isolates in Connecticut, 2017. Open Forum Infectious Diseases 2018, 5: s714-s715. PMCID: PMC6253430, DOI: 10.1093/ofid/ofy210.2049.Peer-Reviewed Original ResearchState public health laboratoriesCRE isolatesNonsusceptible isolatesFosfomycin resistanceAntimicrobial Susceptibility Testing (EUCAST) criteriaCarbapenem-resistant Enterobacteriaceae infectionsOlder patient ageLimited treatment optionsResistance risk factorsSubstantial proportionEnterobacteriaceae clinical isolatesFosfomycin resistance ratePublic health laboratoriesLaboratory Standards InstituteSusceptibility testing criteriaCRE patientsPatient ageEnterobacteriaceae infectionsTreatment optionsRisk factorsResistance ratesWarrants evaluationCarbapenem resistanceBlaKPC geneCLSI criteria